The precision medicine team is focused on genetic musculoskeletal diseases, such as X-linked hypophosphatemia, autosomal dominant hypophosphatemia, and genomic, metabolomics, protemic determinants of bone density, osteoporosis and sarcopenia in aging and chronic disease. These investigators focusing on the causes of these diseases, and working to develop treatments and cures.
“Changes in phosphate metabolism cause pathologic cardiac remodeling in chronic kidney disease (CKD)”
Award period: 2/1/19 to 1/31/23
PI: K. White
Therapeutic potential of HIF-PHDi in the control of bioactive FGF23 in CKD
Active dates: 7/2019-6/2022
PI M. Noonan, IBMG/PhD student in White lab
*priority score of 20.
The effect of etelcalcetide on bone-tissue properties and calcification propensity in end stage kidney disease
Co-PI M. Allen
A clinical trial will be moving forward this summer/fall of a prospective testing of pharmacogenetic guided opioid therapy for acute pain, including patients such as those receiving hip and knee replacements
Multi-PI: T. Skaar
An R35 MIRA grant has been funded from NIGMS focused on the molecular mechanisms that regulate hepatic drug metabolism and contribute to interindividual variability in drug efficacy and toxicity
PI: T. Skaar
P01 development in FGF23/Klotho-related mineral metabolism